Osaic Holdings’s Oruka Therapeutics ORKA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$97.2K Buy
1,170
+357
+44% +$33.6K ﹤0.01% 5029
2026
Q2
$77.4K Buy
813
+716
+738% +$47.7K ﹤0.01% 5145
2026
Q1
$4.76K Buy
97
+93
+2,325% +$3.23K ﹤0.01% 6709
2025
Q4
$121 Buy
4
+3
+300% +$84 ﹤0.01% 7631
2025
Q3
$19 Hold
1
– – ﹤0.01% 7833
2025
Q2
$11 Buy
+1
New +$10 ﹤0.01% 7687
2024
Q1
– Sell
-5
Closed -$93 – 7431
2023
Q4
$93 Hold
5
– – ﹤0.01% 7116
2023
Q3
$110 Hold
5
– – ﹤0.01% 7217
2023
Q2
$115 Hold
5
– – ﹤0.01% 7270
2023
Q1
$113 Hold
5
– – ﹤0.01% 7321
2022
Q4
$0 Hold
5
– – ﹤0.01% 7466
2022
Q3
$0 Hold
5
– – ﹤0.01% 7555
2022
Q2
$0 Hold
5
– – ﹤0.01% 7647
2022
Q1
$0 Sell
5
-4
-44% -$99 ﹤0.01% 7552
2021
Q4
$0 Hold
9
– – ﹤0.01% 7616
2021
Q3
$0 Sell
9
-4
-31% -$148 ﹤0.01% 7346
2021
Q2
$0 Hold
13
– – ﹤0.01% 7156
2021
Q1
$0 Hold
13
– – ﹤0.01% 6973
2020
Q4
$0 Hold
13
– – ﹤0.01% 6611
2020
Q3
$0 Buy
13
+8
+160% +$564 ﹤0.01% 6447
2020
Q2
$0 Hold
5
– – ﹤0.01% 6374
2020
Q1
$0 Buy
+5
New +$272 ﹤0.01% 6212

Other funds holding ORKA

Osaic Holdings's ORKA Position: Q3 2026 in Review

Osaic Holdings increased its Oruka Therapeutics (ORKA) stake by 44% in Q3 2026, buying an estimated $33.6K and bringing the position to 1,170 shares worth $97.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5029.

Osaic Holdings first reported a position in ORKA in Q1 2020 and has held it in 22 quarters since. 175 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • Osaic Holdings held 1,170 shares of Oruka Therapeutics worth $97.2K as of Q3 2026.
  • Osaic Holdings bought 357 Oruka Therapeutics shares in Q3 2026, an estimated $33.6K.
  • Oruka Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q3 2026, its #5029 holding.
  • Osaic Holdings first reported a position in Oruka Therapeutics in Q1 2020 and has held it in 22 quarters since.
  • 175 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Osaic Holdings's 13F filing for Q3 2026, filed 12 Nov 2026.